PF-04971729 (Ertugliflozin): Unlocking Precision in SGLT2-Mediated Diabetes Mellitus Research

Principle Overview: Mechanism and Research Significance

PF-04971729, commonly known as Ertugliflozin, is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor developed for robust interrogation of renal glucose transport in diabetes mellitus research. By blocking SGLT2, PF-04971729 reduces glucose reabsorption in the renal proximal tubule, promoting glucosuria and lowering blood glucose levels—a mechanism central to the management of type 2 diabetes (T2DM). Its high selectivity is demonstrated by a weak inhibitory effect on organic cation transporter 2-mediated [14C]metformin uptake (IC₅₀ = 900 μM), making it ideal for dissecting the SGLT2-mediated glucose transport pathway without off-target interference.

The compound shows rapid oral absorption (Tmax ≈ 1 hour for a 25 mg dose in healthy subjects), with moderate metabolic elimination—about 35.3% excreted unchanged via feces and urine. This pharmacokinetic profile ensures reproducible effects in both in vitro and in vivo settings, paving the way for translational research and advanced mechanistic studies.

To learn more about the compound's molecular features, supplier reliability, and ordering options, visit the PF-04971729 (Ertugliflozin) product page from APExBIO.

Step-by-Step Workflow: Protocols and Enhancements for Reliable Results

1. Compound Preparation and Solubility Optimization

• Reconstitution: PF-04971729 is highly soluble in DMSO (≥50.8 mg/mL) and ethanol (≥51.5 mg/mL), but insoluble in water. For cell-based assays, dissolve the powder in DMSO to create a 10 mM stock solution. Avoid long-term storage of solutions; aliquot and store under inert gas at -20°C for up to two weeks to maintain stability.
• Working Dilutions: Dilute the DMSO stock directly into culture media or assay buffer, ensuring final DMSO concentrations do not exceed 0.1% v/v to avoid cytotoxicity or assay interference.

2. In Vitro SGLT2 Inhibition Assay

• Model Selection: Use HEK293 or CHO cells stably expressing human SGLT2 for functional uptake assays. Include parental (non-transfected) cells as negative controls to confirm pathway specificity.
• Assay Principle: Incubate cells with radiolabeled or fluorescent glucose analogs (e.g., [14C]-α-methyl-D-glucopyranoside) in the presence of escalating concentrations of PF-04971729. Quantify uptake inhibition to determine IC₅₀ values.
• Controls: Use known SGLT2 inhibitors and SGLT1-expressing cells to benchmark selectivity.

3. In Vivo Glucose Reabsorption Inhibition

• Dosing: Prepare oral gavage formulations of PF-04971729 in 0.5% methylcellulose (with ≤0.5% DMSO if necessary). Standard rodent doses range from 1 to 10 mg/kg, based on published pharmacodynamic data.
• Sampling: Collect urine at defined intervals (e.g., 0–6, 6–12, 12–24 hours post-dose) to measure urinary glucose excretion. Parallel plasma sampling enables assessment of pharmacokinetics (PK/PD modeling).

4. Transporter Selectivity Profiling

• Organic Cation Transporter 2 (OCT2) Assay: Test PF-04971729 up to 1 mM in OCT2-expressing cells using [14C]metformin uptake. Expect minimal inhibition (IC₅₀ ≈ 900 μM), confirming high SGLT2 selectivity.

Advanced Applications & Comparative Advantages

PF-04971729's high selectivity and well-characterized pharmacokinetics enable advanced interrogation of renal glucose transport, SGLT2-mediated glucose reabsorption, and transporter crosstalk:

• Dissecting SGLT2 vs. SGLT1 Functions: In dual-transfected cell systems or SGLT2/SGLT1 knockout models, PF-04971729 facilitates precise measurement of SGLT2-specific effects, minimizing confounding by SGLT1 or other renal transporters.
• Metabolic and Cardiovascular Endpoints: The compound's predictable PK profile supports studies of glucose homeostasis, insulin sensitivity, and even cardiovascular risk factors in animal models.
• Fracture Risk and Translational Relevance: As highlighted in a recent systematic review and network meta-analysis, SGLT2 inhibitors such as Ertugliflozin may be neutral or potentially increase fracture risk in T2DM patients, underscoring the need for mechanistic research into bone metabolism and safety pharmacology.

For an expanded discussion on precise renal assay design and selectivity validation, see "PF-04971729 (Ertugliflozin): Selective SGLT2 Inhibitor for Renal Glucose Transport Research", which complements this workflow by offering deeper molecular insights and assay benchmarking. Additionally, "PF-04971729 (Ertugliflozin): Empowering Translational Scientists" extends the discussion to translational model applications, while "PF-04971729: Advanced Insights into SGLT2 Pharmacology" provides new perspectives on fracture risk and cardiometabolic endpoints.

Troubleshooting & Optimization Tips

• Solubility Challenges: If precipitation occurs during aqueous dilution, increase DMSO stock concentration or use ethanol as an alternative solvent, maintaining solvent tolerance for your biological system. For in vivo work, ensure complete dispersion in methylcellulose or similar vehicles.
• Cell Viability & DMSO Toxicity: Monitor cell health at each DMSO percentage increment. If toxicity is observed, further dilute the compound or use ethanol where compatible.
• Assay Interference: PF-04971729 is chemically stable but sensitive to prolonged exposure to ambient light and repeated freeze-thaw. Prepare fresh aliquots and minimize freeze-thaw cycles to maintain compound integrity.
• Transporter Selectivity: Confirm SGLT2-specific inhibition by including SGLT1 and OCT2 counter-screens. Use the high IC₅₀ for OCT2 inhibition (900 μM) as a benchmark for selectivity; significant off-target effects at experimental concentrations are unlikely.
• Pharmacokinetic Variability: For in vivo studies, standardize animal fasting states and circadian timing of dosing to minimize PK/PD variability. Record urine volumes precisely to ensure accurate glucosuria quantification.

Future Outlook: Expanding the Impact of SGLT2 Inhibitor Research

With PF-04971729 (Ertugliflozin) in phase 2 clinical trials, its research applications are poised to extend beyond glucose reabsorption inhibition. Forthcoming studies are expected to explore:

• Renal and Cardiovascular Safety: Mechanistic dissection of SGLT2 inhibitor effects on renal hemodynamics, glomerular filtration, and long-term cardiovascular endpoints.
• Bone Metabolism and Fracture Risk: Given the nuanced findings of the recent systematic review—wherein some SGLT2 inhibitors may modestly increase fracture risk—there is growing demand for molecular studies into osteoblast/osteoclast signaling and bone microarchitecture in T2DM models.
• Transporter Interactions in Polypharmacy: The high selectivity of PF-04971729 for SGLT2 over OCT2 supports combination studies with metformin or other antidiabetic agents, modeling clinical polypharmacy scenarios while minimizing transporter-mediated drug-drug interactions.
• Personalized and Precision Medicine Approaches: As research elucidates gene-environment-drug interactions in diabetes mellitus, PF-04971729 will serve as a benchmark for the next generation of selective, low-risk oral SGLT2 inhibitors for diabetes research.

By leveraging the rigorous supply chain and quality standards of APExBIO, researchers can expect reliable, reproducible results critical for publication and regulatory submissions.

Conclusion

PF-04971729 (Ertugliflozin) stands out as a best-in-class selective SGLT2 inhibitor for academic and translational diabetes mellitus research. Its robust solubility profile, quantifiable selectivity, and well-documented pharmacokinetics enable advanced assay design and meaningful mechanistic discoveries. Whether exploring renal glucose transport, pharmacokinetic-pharmacodynamic modeling, or transporter crosstalk in complex disease models, this compound—available from APExBIO—equips researchers with the precision tools needed for next-generation diabetes research.